For epilepsy: A prescription cannabidiol product (Epidiolex) has been used. The recommended starting dose is usually 2.5 mg/kg twice daily (5 mg/kg/day). After one week the dose can be increased to 5 mg/kg twice daily (10 mg/kg/day). If the person doesn't respond to this dose, the maximum recommended is 10 mg/kg twice daily (20 mg/kg/day). In some research, higher doses of up to 50 mg/kg daily have been used. There is no strong scientific evidence that nonprescription cannabidiol products are beneficial for epilepsy.
There’s a growing consensus that cannabis is a highly effective treatment for many kinds of neuropathic pain. A 2015 study published in Neurotherapeutics states, “Clinical studies largely affirm that neuropathic pain patients derive benefits from cannabinoid treatment.” But much of the human-based research (like this study) on CBD and nerve pain has centered around the efficacy of the FDA-approved medication Sativex, which includes both THC and CBD. Research on the best CBD for pain isolated from THC is still limited when it comes to neuropathic pain. There are exceptions, though:
Statement from FDA Commissioner Scot Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency's regulation of products containing cannabis and cannabis-derived compounds. U.S. Food and Drug Administration Web site. Available at: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-and-agencys. (Accessed May 7, 2019).
As mentioned above, CBDPure is a natural oil extracted through cold pressing and CO2 procedures from Cannabis sativa. Specialists have identified over 80 compounds known as cannabinoids. Their research so far showed that CBD is the predominant cannabinoid, accounting for over 40% of the cannabinoids concentration. It is also the most beneficial for human health, at least from the cannabinoids studied so far.